Empowered Patient Podcast

Terry Weber is the CEO of BioTE and is on a mission to educate medical professionals about the need to address the hormone levels in patients as they age. With a personalized approach, BioTE focuses on providing hormone therapy to help patients maintain their quality of life and not just be dismissed as getting old when they report discomfort, sexual dysfunction, and loss of muscle mass.

Terry explains, "At BioTE we don't just do hormone treatment. We try to optimize the individual's hormones, and that would be estrogen and testosterone, both for men and women. Testosterone's very important for women. Also, looking at the thyroid and adrenals. What we look to see is how do we balance those hormones in the individuals so that they really feel their absolute best. We take blood tests, and we have very in-depth questionnaires because everyone's reaction to hormone levels is very personal."

"BioTE's history has been to focus on putting a light on testosterone for women because it's such a critical hormone. Most people assume that testosterone is just for men, and that's not true at all. What BioTE has brought to the market is a real focus on women's needs and the need for testosterone in women's bodies and how important that is in the long run for their general health. We've been disruptive in that way."

#BioTE #HealthyAging #WomensHealth #HormoneTherapy #Hormones #HormonalInbalance #Testosterone #Estrogen

BioTE.com

Listen to the podcast here

Terry Weber is the CEO of BioTE and is on a mission to educate medical professionals about the need to address the hormone levels in patients as they age. With a personalized approach, BioTE focuses on providing hormone therapy to help patients maintain their quality of life and not just be dismissed as getting old when they report discomfort, sexual dysfunction, and loss of muscle mass.

Terry explains, "At BioTE we don't just do hormone treatment. We try to optimize the individual's hormones, and that would be estrogen and testosterone, both for men and women. Testosterone's very important for women. Also, looking at the thyroid and adrenals. What we look to see is how do we balance those hormones in the individuals so that they really feel their absolute best. We take blood tests, and we have very in-depth questionnaires because everyone's reaction to hormone levels is very personal."

"BioTE's history has been to focus on putting a light on testosterone for women because it's such a critical hormone. Most people assume that testosterone is just for men, and that's not true at all. What BioTE has brought to the market is a real focus on women's needs and the need for testosterone in women's bodies and how important that is in the long run for their general health. We've been disruptive in that way."

#BioTE #HealthyAging #WomensHealth #HormoneTherapy #Hormones #HormonalInbalance #Testosterone #Estrogen

BioTE.com

Download the transcript here

Dr. Diem Nguyen is the CEO of Xalud Therapeutics, a DNA delivery gene therapy company striving to develop and deliver medicines for large, broad-based disease indications like chronic inflammatory diseases, particularly musculoskeletal diseases like osteoarthritis of the knee and as well as neurodegenerative diseases like MS and ALS. Earlier in her career, Diem was the global President of Pfizer, covering multiple therapeutic areas, and has joined Xalud because of their ground-breaking DNA delivery platform.

Diem explains, "Gene therapy means a lot of things to a lot of people. And the first, I would say, is most people, when they think about gene therapies, think about viral AAV gene therapy. And a lot of promise is associated with that type of platform because you're seeing this potential, particularly in rare diseases. The challenges associated with AAV sometimes are the safety profile associated with that product. Our particular gene therapy is DNA gene therapy, so we do not have the challenges with genome integration, which allows us to have a potentially stronger safety profile."

"I want to be very clear when I say disease modification because it can mean many things from a definition perspective to different audiences. What I want to say specifically about our product, XT-150, is we're not looking to treat pain associated with osteoarthritis of the knee by just blocking the pain or masking the pain. What we're trying to do is help your body restore homeostasis."

"What we're saying is we're supplementing your body with interleukin-10, which then allows you to have your body naturally reduce pro-inflammatory cytokines, which then reduces the inflammation."

#XaludTherapeutics #GeneTherapy #InflammatoryDiseases #Cytokines #Inflammation #Osteoarthritis #NeurodegenerativeDiseases #ALS #MS

XaludThera.com

Listen to the podcast here

Dr. Diem Nguyen is the CEO of Xalud Therapeutics, a DNA delivery gene therapy company striving to develop and deliver medicines for large, broad-based disease indications like chronic inflammatory diseases, particularly musculoskeletal diseases like osteoarthritis of the knee and as well as neurodegenerative diseases like MS and ALS. Earlier in her career, Diem was the global President of Pfizer, covering multiple therapeutic areas, and has joined Xalud because of their ground-breaking DNA delivery platform.

Diem explains, "Gene therapy means a lot of things to a lot of people. And the first, I would say, is most people, when they think about gene therapies, think about viral AAV gene therapy. And a lot of promise is associated with that type of platform because you're seeing this potential, particularly in rare diseases. The challenges associated with AAV sometimes are the safety profile associated with that product. Our particular gene therapy is DNA gene therapy, so we do not have the challenges with genome integration, which allows us to have a potentially stronger safety profile."

"I want to be very clear when I say disease modification because it can mean many things from a definition perspective to different audiences. What I want to say specifically about our product, XT-150, is we're not looking to treat pain associated with osteoarthritis of the knee by just blocking the pain or masking the pain. What we're trying to do is help your body restore homeostasis."

"What we're saying is we're supplementing your body with interleukin-10, which then allows you to have your body naturally reduce pro-inflammatory cytokines, which then reduces the inflammation."

#XaludTherapeutics #GeneTherapy #InflammatoryDiseases #Cytokines #Inflammation #Osteoarthritis #NeurodegenerativeDiseases #ALS #MS

XaludThera.com

Download the transcript here

Sabrina Johnson is the Founder, President, and CEO of Daré Bioscience. Sabrina points out that there are several unmet needs in women's health and that many of the indications or conditions that women are dealing with are not life-threatening but affect their quality of life. Applying technologies created by smaller companies and academic institutions, Daré aims to become a pipeline for companies that have a global commitment to improving women's health.

Sabrina explains, "Our business model is to really be that innovation accelerator that starts with finding and identifying that persistent unmet need. And that's where we start. What is that condition that is not adequately addressed today for her? Developing a target product profile, what would the product look like that might be best suited to address that condition for her? We then go out and look for a technology that has a proof of concept that it should address that and hit that target product profile. We bring that into Daré into our portfolio. We advance it through development, and then ultimately, we seek to bring that product to market in whatever way makes the most sense for that product. And sometimes that's going to be by being that pipeline resource to companies like Bayer and Organon. And I mentioned both of those because we have a collaboration with each of them now."

@DareBioscience #WomensHealth #GenderInequality #Healthcare #ReproductiveHealth #SexualHealth #Biotech #DrugDevelopment

darebioscience.com

Listen to the podcast here

Sabrina Johnson is the Founder, President, and CEO of Daré Bioscience. Sabrina points out that there are several unmet needs in women's health and that many of the indications or conditions that women are dealing with are not life-threatening but affect their quality of life. Applying technologies created by smaller companies and academic institutions, Daré aims to become a pipeline for companies that have a global commitment to improving women's health.

Sabrina explains, "Our business model is to really be that innovation accelerator that starts with finding and identifying that persistent unmet need. And that's where we start. What is that condition that is not adequately addressed today for her? Developing a target product profile, what would the product look like that might be best suited to address that condition for her? We then go out and look for a technology that has a proof of concept that it should address that and hit that target product profile. We bring that into Daré into our portfolio. We advance it through development, and then ultimately, we seek to bring that product to market in whatever way makes the most sense for that product. And sometimes that's going to be by being that pipeline resource to companies like Bayer and Organon. And I mentioned both of those because we have a collaboration with each of them now."

@DareBioscience #WomensHealth #GenderInequality #Healthcare #ReproductiveHealth #SexualHealth #Biotech #DrugDevelopment

darebioscience.com

Download the transcript here

Dr. Kimberly Kilby is the Vice-President and Medical Director of Health and Wellbeing at MVP Health Care. Trained as a family and preventive physician, Kimberly is focused on the patient journey and expanding the options for virtual care. MVP collaborates with virtual care providers and other digital health solutions, supporting virtual primary care, urgent care, chronic care management, and specialty care.

Kimberly explains, "We want to be sure that patients are finding options for virtual care that are actually high-quality medicine but also thoughtfully integrated into the rest of their care continuum. That's part of the professional reason why a physician is dedicated to that key customer experience as you expand options in the virtual care space."

"A lot of the data is showing that patient and consumer preferences within healthcare have obviously changed dramatically, and patients are looking for more convenience and availability. And I'm really charged with determining which of the innovative options people are migrating to are actually high value and improve care and don't really add waste to the system."

@MVPHealthCare #DigitalHealth #Telemedicine #VirtualPrimaryCare #VirtualUrgentCare

MVPHealthCare.com

Listen to the podcast here

Dr. Kimberly Kilby is the Vice-President and Medical Director of Health and Wellbeing at MVP Health Care. Trained as a family and preventive physician, Kimberly is focused on the patient journey and expanding the options for virtual care. MVP collaborates with virtual care providers and other digital health solutions, supporting virtual primary care, urgent care, chronic care management, and specialty care.

Kimberly explains, "We want to be sure that patients are finding options for virtual care that are actually high-quality medicine but also thoughtfully integrated into the rest of their care continuum. That's part of the professional reason why a physician is dedicated to that key customer experience as you expand options in the virtual care space."

"A lot of the data is showing that patient and consumer preferences within healthcare have obviously changed dramatically, and patients are looking for more convenience and availability. And I'm really charged with determining which of the innovative options people are migrating to are actually high value and improve care and don't really add waste to the system."

@MVPHealthCare #DigitalHealth #Telemedicine #VirtualPrimaryCare #VirtualUrgentCare

MVPHealthCare.com

Download the transcript here

Mai-Britt Zocca is the Founder, CEO, and President of IO Biotech, a clinical stage biopharmaceutical company headquartered in Denmark. They are developing immune modeling cancer therapies based on their T-win technology. Using these cancer vaccines, pre-existing T-cells are being directed in patients to attack and eliminate solid tumors.

Mai-Britt explains, "Currently, we have a leading program that is in Phase 3. So, this is in first-line advanced melanoma. We have a breakthrough therapy designation granted by the FDA, based on the earlier data that we have seen in melanoma. Our targets also are able to be used in other cancer indications. We are not melanoma per se. We are already running trials in first-line solid tumors where we are including also lung, head, neck, and bladder cancer."

"What we do is vaccinate, as I mentioned before, and the vaccination process is a combination of first a booster program, where we give vaccination or injections several times. Then we have a maintenance phase after that. This is where we see that after these vaccinations, where we vaccinate against the tumor environment, we generate the T-cells that can react towards the immune suppressive mechanisms that we know are hindering the effect of the T-cells in these patients."

#IOBiotech #Melanoma #CancerVaccine #Immunotherapy #Cancer #ImmunoOncology

IOBiotech.com

Listen to the podcast here

Mai-Britt Zocca is the Founder, CEO, and President of IO Biotech, a clinical stage biopharmaceutical company headquartered in Denmark. They are developing immune modeling cancer therapies based on their T-win technology. Using these cancer vaccines, pre-existing T-cells are being directed in patients to attack and eliminate solid tumors.

Mai-Britt explains, "Currently, we have a leading program that is in Phase 3. So, this is in first-line advanced melanoma. We have a breakthrough therapy designation granted by the FDA, based on the earlier data that we have seen in melanoma. Our targets also are able to be used in other cancer indications. We are not melanoma per se. We are already running trials in first-line solid tumors where we are including also lung, head, neck, and bladder cancer."

"What we do is vaccinate, as I mentioned before, and the vaccination process is a combination of first a booster program, where we give vaccination or injections several times. Then we have a maintenance phase after that. This is where we see that after these vaccinations, where we vaccinate against the tumor environment, we generate the T-cells that can react towards the immune suppressive mechanisms that we know are hindering the effect of the T-cells in these patients."

#IOBiotech #Melanoma #CancerVaccine #Immunotherapy #Cancer #ImmunoOncology

IOBiotech.com

Download the transcript here